United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride, usp is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hydrochloride, usp are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hydrochloride, usp, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hydrochloride, usp. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. clinical studies have shown that when dopamine hydrochloride, usp is administered before urine flow has diminished to levels of approximately 0.3 ml/minute, prognosis is more favorable. nevertheless, in a number of oliguric or anuric patients, administration of dopamine hydrochloride, usp has resulted in an increase in urine flow, which in some cases reached normal levels. dopamine hydrochloride, usp may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. it should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. low cardiac output – increased cardiac output is related to dopamine’s direct inotropic effect on the myocardium. increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. increase in cardiac output has been associated with either static or decreased systemic vascular resistance (svr). static or decreased svr associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. in many instances the renal fraction of the total cardiac output has been found to increase. increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. hypotension – hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine hydrochloride, usp which have little effect on svr. at high therapeutic doses, dopamine’s alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished svr. as in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. therefore, it is suggested that the physician administer dopamine hydrochloride, usp as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. dopamine hcl should not be used in patients with pheochromocytoma. dopamine hcl should not be administered to patients with uncorrected tachyarrhythmias or ventricular fibrillation.

United States - English - NLM (National Library of Medicine)

henry schein, inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hcl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hcl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hcl, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hcl. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the p

United States - English - NLM (National Library of Medicine)

henry schein, inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hcl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hcl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hcl, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hcl. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the p

Kenya - English - Pharmacy and Poisons Board

innocia lifesciences pvt. ltd block a, no.12, balaji nagar, ambattur, - dapagliflozin propanediol monohydrate & metformin… - tablet - each film coated tablet contains dapagliflozin… - metformin and dapagliflozin

Kenya - English - Pharmacy and Poisons Board

m/s. innocia lifesciences pvt. ltd. 12, balaji nagar, ambattur, chennai – 53, - dapagliflozin propanediol monohydrate & metformin… - tablet - each film coated tablet contains dapagliflozin… - metformin and dapagliflozin

Kenya - English - Pharmacy and Poisons Board

m/s. innocia lifesciences pvt. ltd. block a, no.12, balaji nagar, ambattur, chennai – - dapagliflozin propanediol monohydrate & metformin… - tablet - each film coated tablet contains dapagliflozin… - metformin and dapagliflozin

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - empagliflozin 12.5mg;  ; metformin hydrochloride 1000mg;   - film coated tablet - 12.5mg/1000mg - active: empagliflozin 12.5mg   metformin hydrochloride 1000mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry purple 02b200006 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - empagliflozin 12.5mg;  ; metformin hydrochloride 500mg;   - film coated tablet - 12.5mg/500mg - active: empagliflozin 12.5mg   metformin hydrochloride 500mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry pink 02b20004 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - empagliflozin 12.5mg;  ; metformin hydrochloride 850mg;   - film coated tablet - 12.5mg/850mg - active: empagliflozin 12.5mg   metformin hydrochloride 850mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry pink 02b240006 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - empagliflozin 5mg;  ; metformin hydrochloride 1000mg;   - film coated tablet - 5mg/1000mg - active: empagliflozin 5mg   metformin hydrochloride 1000mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220012 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.